|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 401/14 | |
| A61P 7/12 | |||
| A61P 9/00 | |||
| A61P 43/00 |
| (11) | Number of the document | 3169325 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15822307.3 |
| Date of filing the European patent application | 2015-07-15 | |
| (97) | Date of publication of the European application | 2017-05-24 |
| (45) | Date of publication and mention of the grant of the patent | 2021-04-28 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/040659 |
| Date | 2015-07-15 |
| (87) | Number | WO 2016/011209 |
| Date | 2016-01-21 |
| (30) | Number | Date | Country code |
| 201462025203 P | 2014-07-16 | US | |
| PCT/US2014/0728 | 2014-12-30 | WO | |
| 201562187786 P | 2015-07-01 | US | |
| 201562190223 P | 2015-07-08 | US |
| (72) |
MCDONALD, Andrew, US
QIAN, Shawn, US
|
| (73) |
Attune Pharmaceuticals, Inc.,
250 W. 55th Street, 34th Floor,, New York, NY 10019,
US
|
| (54) | THERAPEUTIC INHIBITORY COMPOUNDS |
| THERAPEUTIC INHIBITORY COMPOUNDS |